Почетна › Немалоклетни карцином плућа › Округ Колумбија › Washington
Kliničke studije za Немалоклетни карцином плућа u gradu Washington, DC
55 studija za Немалоклетни карцином плућа traži učesnike na lokacijama u gradu Washington i okolini (u krugu od oko 30 milja). Otvorite studiju da biste videli ko može da učestvuje i kako kontaktirati tim studije.
Zvanični tekst studije (na engleskom)
Tražite učesnike za studiju? Istaknite je na vrhu ove stranice — $99 za 30 dana →
A Clinical Trial to Test if an Investigational Combination Therapy With BNT326 and BNT327 is Safe and Potentially Beneficial for People With Advanced Non-small Cell Lung Cancer (NSCLC)
Тражи се учесникФаза 1/2
- Georgetown University - Lombardi Comprehensive Cancer Center, Washington D.C.
This is a Study to Learn About How the Combination of the Study Medicines Sigvotatug Vedotin Plus Pembrolizumab Works in People With Non-small Cell Lung Cancer With High Levels of PD-L1.
Тражи се учесникФаза 3
- Washington DC Veterans Affairs Medical Center, Washington D.C.
Testing the Addition of a Type of Drug Called Immunotherapy to the Usual Chemotherapy Treatment for Non-small Cell Lung Cancer, an ALCHEMIST Treatment Trial (Chemo-IO [ACCIO])
Тражи се учесникФаза 3
- Kaiser Permanente-Capitol Hill Medical Center, Washington D.C.
- MedStar Georgetown University Hospital, Washington D.C.
- MedStar Washington Hospital Center, Washington D.C.
- и још 1
A Phase 1 Study of PLN-101095 in Adults With Advanced or Metastatic Solid Tumors
Тражи се учесникФаза 1
- Georgetown University Medical Center, Washington D.C.
Biospecimen Procurement for Center for Immuno-Oncology Immunotherapy Protocols
Тражи се учесникОпсервациона студија
- National Institutes of Health Clinical Center, Bethesda · 7 ми удаљено
Trial of Therapeutic Cancer Vaccine OSE2101 in Patients With Non-Small Cell Lung Cancer and Secondary Resistance to Immune Checkpoint Inhibitor
Тражи се учесникФаза 3
- Georgetown Lombardi Comprehensive Cancer Center, Washington D.C.
Beamion LUNG-1: A Study to Test Different Doses of Zongertinib in People With Different Types of Advanced Cancer (Solid Tumours With Changes in the HER2 Gene)
Тражи се учесникФаза 1
- Georgetown University, Washington D.C.
Study of Izalontamab Brengitecan (BMS-986507) in Combination With Osimertinib Versus Osimertinib Monotherapy or Osimertinib in Combination With Platinum-based Chemotherapy for EGFRmt Non-small Cell Lung Cancer (IZABRIGHT-Lung02)
Тражи се учесникФаза 3
- Local Institution - 0161, Washington D.C.
- Local Institution - 0523, Silver Spring · 7 ми удаљено
A Study of Therapeutic Drug Monitoring-Based Atezolizumab Dosing
Тражи се учесникФаза 1
- National Institutes of Health Clinical Center, Bethesda · 7 ми удаљено
A Study to Learn About the Study Medicine Called PF-08046054/SGN-PDL1V Versus Docetaxel in Adult Participants With Previously-Treated Programmed Cell Death Ligand 1 (PD-L1) Positive Non-Small-Cell Lung Cancer (NSCLC)
Тражи се учесникФаза 3
- Maryland Oncology Hematology, P.A., Silver Spring · 7 ми удаљено
- Maryland Oncology Hematology, P.A., Bethesda · 7 ми удаљено
- Maryland Oncology Hematology, P.A, Largo · 11 ми удаљено
A Study Evaluating the Efficacy and Safety of Divarasib and Pembrolizumab Versus Pembrolizumab and Pemetrexed and Carboplatin or Cisplatin in Participants With Previously Untreated, KRAS G12C-Mutated, Advanced or Metastatic Non-Squamous Non-Small Cell Lung Cancer
Тражи се учесникФаза 3
- Walter Reed National Military Medical Center, Bethesda · 7 ми удаљено
Study of Olomorasib (LY3537982) in Combination With Standard of Care in Participants With Resected or Unresectable KRAS G12C-mutant Non-Small Cell Lung Cancer
Тражи се учесникФаза 3
- Sibley Memorial Hospital, Washington D.C.
A Study of BH-30643 in Subjects With Locally Advanced or Metastatic NSCLC Harboring EGFR and/or HER2 Mutations
Тражи се учесникФаза 1/2
- Georgetown University Medical Center, Washington D.C.
VMD-928 Monotherapy and in Combination With Pembrolizumab to Treat TrkA Overexpression Driven Solid Tumors or Lymphoma
Тражи се учесникФаза 1/2
- The George Washington University Cancer Center (site 212), Washington D.C.
A Study of First-Line Olomorasib (LY3537982) and Pembrolizumab With or Without Chemotherapy in Patients With Advanced KRAS G12C-Mutant Non-small Cell Lung Cancer
Тражи се учесникФаза 3
- Sibley Memorial Hospital, Washington D.C.
Testing Osimertinib as a Treatment for Lung Cancers With an EGFR Exon 20 Change
Тражи се учесникФаза 2
- MedStar Georgetown University Hospital, Washington D.C.
A Study of Amivantamab in Participants With Advanced or Metastatic Solid Tumors Including Epidermal Growth Factor Receptor (EGFR)-Mutated Non-Small Cell Lung Cancer
Тражи се учесникФаза 2
- Johns Hopkins Office of Capital Region Research - Sibley Memorial Hospital, Washington D.C.
Study to Assess the Efficacy and Safety of Rina-S in Participants With Non-small Cell Lung Cancer
Тражи се учесникФаза 2
- MedStar Georgetown University Hospital, Washington D.C.
Safety, Efficacy, and Pharmacokinetics of BNT327 in Combination With Chemotherapy and Other Investigational Agents for Lung Cancer (ROSETTA Lung-02)
Тражи се учесникФаза 2/3
- MedStar Georgetown-MedStar Georgetown Transplant Institute University Hospital (MGUH), Washington D.C.
- MEDSTAR Washington Hospital Center (MedStar Health Research Institute), Washington D.C.
Beamion LUNG-3: Adjuvant Zongertinib vs Standard Treatment in People With Completely Resected Stage II-IIIB NSCLC Harboring Activating HER2 TKD Mutations
Тражи се учесникФаза 3
- George Washington University Cancer Center, Washington D.C.
Phase 2 Trial of Adagrasib Monotherapy and in Combination With Pembrolizumab and a Phase 3 Trial of Adagrasib in Combination in Patients With a KRAS G12C Mutation KRYSTAL-7
Тражи се учесникФаза 2/3
- Local Institution - 007-5476, Washington D.C.
Administration of Autologous T-Cells Genetically Engineered to Express T-Cell Receptors Reactive Against Neoantigens in People With Metastatic Cancer
Тражи се учесникФаза 2
- National Institutes of Health Clinical Center, Bethesda · 7 ми удаљено
DB-1311 in Combination With BNT327 or DB-1305 in Advanced/Metastatic Solid Tumors
Тражи се учесникФаза 2
- USA11-0, Bethesda · 7 ми удаљено
Study of STK-012 Alone and With Other Treatments in Patients With Advanced Lung Cancer and Other Cancers
Тражи се учесникФаза 1/2
- Georgetown University, Washington D.C.
A Global Phase III Study of Rilvegostomig or Pembrolizumab Plus Chemotherapy for First-Line Treatment of Locally Advanced or Metastatic Squamous Non-small Cell Lung Cancer (NSCLC)
Тражи се учесникФаза 3
- Research Site, Bethesda · 7 ми удаљено
- Research Site, Bethesda · 7 ми удаљено
Pembrolizumab With or Without Maintenance Sacituzumab Tirumotecan (Sac-TMT; MK-2870) in Metastatic Squamous Non-small Cell Lung Cancer (NSCLC) [MK-2870-023]
Тражи се учесникФаза 3
- Washington Hospital Center ( Site 0037), Washington D.C.
Study to Evaluate Sutetinib Maleate Capsule in Locally Advanced or Metastatic Non-small Cell Lung Cancer
Тражи се учесникФаза 2
- Georgetown Lombardi Comprehensive Cancer Center, Washington D.C.
A Study To Assess the Safety, Tolerability, and Efficacy of Imzokitug in Combination With Pumitamig and Platinum-Doublet Chemotherapy (PDCT) Versus Pumitamig and PDCT as First-line Treatment for Participants With Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC)
Тражи се учесникФаза 2
- Local Institution - 0183, Washington D.C.
A Study to Investigate Ubamatamab With and Without Marlotamig (REGN7075) in Adult Participants With Advanced/Metastatic Non-Small Cell Lung Cancer (NSCLC)
Тражи се учесникФаза 2
- Georgetown University, Washington D.C.
Safety and Tolerability of TNG456 Alone and in Combination With Abemaciclib in Patients With Solid Tumors With MTAP Loss
Тражи се учесникФаза 1/2
- Sibley Memorial Hospital, Washington D.C.
T Cell Receptor Immunotherapy for Patients With Metastatic Non-Small Cell Lung Cancer
Тражи се учесникФаза 2
- National Institutes of Health Clinical Center, Bethesda · 7 ми удаљено
Study of RAS(ON) Inhibitors in Patients With Advanced RAS-mutated NSCLC
Тражи се учесникФаза 1/2
- Georgetown University Medical Center, Washington D.C.
Tissue Procurement and Natural History Study of People With Non-Small Cell Lung Cancer, Small Cell Lung Cancer, Extrapulmonary Small Cell Cancer, Pulmonary Neuroendocrine Tumors, and Thymic Epithelial Tumors
Тражи се учесникОпсервациона студија
- National Institutes of Health Clinical Center, Bethesda · 7 ми удаљено
Phase 1/2 Trial of S241656 in Selected RAS/MAPK Mutation- Positive Malignancies
Тражи се учесникФаза 1/2
- Georgetown University Lombardi Cancer Center, Washington D.C.
- Sibley Memorial Hospital, Washington D.C.
A Study to Assess Zipalertinib Versus Placebo in Participants With Early Stage NSCLC With Uncommon EGFR Mutations, Following Complete Tumor Resection
Тражи се учесникФаза 3
- Georgetown University School of Medicine, Washington D.C.
Targeted Treatment for Advanced Non-Small Cell Lung Cancer That Has a MET Exon 14 Skipping Gene Change (An Expanded Lung-MAP Treatment Trial)
Тражи се учесникФаза 2
- Kaiser Permanente-Capitol Hill Medical Center, Washington D.C.
- Kaiser Permanente - Largo Medical Center, Largo · 11 ми удаљено
Adding the Immunotherapy Drug Cemiplimab to Usual Treatment for People With Advanced Non-Small Cell Lung Cancer Who Had Previous Treatment With Platinum Chemotherapy and Immunotherapy (An Expanded Lung-MAP Treatment Trial)
Тражи се учесникФаза 2/3
- Kaiser Permanente-Capitol Hill Medical Center, Washington D.C.
- Kaiser Permanente - Largo Medical Center, Largo · 11 ми удаљено
Symbiotic-Lung-01 : A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Adult Participants With Locally Advanced or Metastatic Non-Small Cell Lung Cancer
Тражи се учесникФаза 3
- Maryland Oncology Hematology, P.A., Silver Spring · 7 ми удаљено
- Maryland Oncology Hematology, P.A., Bethesda · 7 ми удаљено
- Maryland Oncology Hematology, P.A., Largo · 11 ми удаљено
Neoadjuvant Chemo-Immunotherapy and Surgical Resection in Locally Advanced Non-small Cell Lung Cancer With N3 Lymph Node or Other High Risk Features
Тражи се учесникФаза 2
- Lombardi Comprehensive Cancer Center, Georgetown University, Washington D.C.
A Study of PHN-012 in Patients With Advanced Solid Tumors
Тражи се учесникФаза 1
- PHN-012-001 Site, Washington D.C.
A Global Phase III Study of Rilvegostomig or Pembrolizumab Monotherapy for First-Line Treatment of PD-L1-high Metastatic Non-small Cell Lung Cancer
Тражи се учесникФаза 3
- Research Site, Silver Spring · 7 ми удаљено
- Research Site, Bethesda · 7 ми удаљено
Evaluate BL-B01D1 in Patients With Metastatic or Unresectable Non-Small Cell Lung Cancer (NSCLC) and Other Solid Tumors
Тражи се учесникФаза 1
- Georgetown University Medical Center, Washington D.C.
Phase III, Open-label Study of First-line Osimertinib With or Without Datopotamab Deruxtecan for EGFRm Locally Advanced or Metastatic Non-small Cell Lung Cancer
Тражи се учесникФаза 3
- Research Site, Bethesda · 7 ми удаљено
Testing Proton Craniospinal Radiation Therapy Versus the Usual Radiation Therapy for Leptomeningeal Metastasis, RADIATE-LM Trial
Тражи се учесникФаза 3
- Sibley Memorial Hospital, Washington D.C.
A Study of a Selective T Cell Receptor (TCR) Targeting, Bifunctional Antibody-fusion Molecule STAR0602 in Participants With Advanced Solid Tumors
Тражи се учесникФаза 1/2
- National Institutes of Health, Bethesda · 7 ми удаљено
Study of NXP900 With Osimertinib in Subjects With Advanced, EGFR-Mutated Non-Small Cell Lung Cancer
Тражи се учесникФаза 1
- Maryland Oncology Hematology, Calverton · 12 ми удаљено
Gilteritinib for the Treatment of ALK NSCLC
Тражи се учесникФаза 1
- Georgetown University, Washington D.C.
Comparing Combinations of Targeted Drugs for Advanced Non-Small Cell Lung Cancer That Has EGFR and MET Gene Changes (A Lung-MAP Treatment Trial)
Тражи се учесникФаза 2
- Kaiser Permanente-Capitol Hill Medical Center, Washington D.C.
- Kaiser Permanente - Largo Medical Center, Largo · 11 ми удаљено
Phase 3 Study of Taletrectinib vs Placebo as an Adjuvant Therapy in ROS1 Positive NSCLC (TRUST-IV)
Тражи се учесникФаза 3
- Georgetown University Medical Cener (GUMC), Washington D.C.
Durvalumab and Tremelimumab in Combination With Chemotherapy in HIV-infected Patients With Non-small Cell Lung Cancer
Тражи се учесникФаза 2
- Georgetown Lombardi Comprehensive Cancer Center, Washington D.C.
- Medstar Washington Hospital Center, Washington D.C.
Phase I Study of Tolododekin Alfa (ANK-101) in Advanced Solid Tumors
Тражи се учесникФаза 1
- National Cancer Institute, Bethesda · 7 ми удаљено
Repositioning Immunotherapy in VetArans With Lung Cancer
Тражи се учесникФаза 2
- VA Central Office, Washington, DC, Washington D.C.
GEMINI-NSCLC: NSCLC Biomarker Study
Тражи се учесникОпсервациона студија
- The Center for Cancer and Blood Disorder, Bethesda · 7 ми удаљено
SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry
Тражи се учесникОпсервациона студија
- Massive Bio SYNERGY-AI site, Silver Spring · 7 ми удаљено
- Massive Bio SYNERGY-AI site, Bethesda · 7 ми удаљено
FIH Trial of VERT-002 in Patients With Locally Advanced or Metastatic Solid Tumors With MET Alterations
Тражи се учесникФаза 1/2
- Georgetown Lombardi Comprehensive Cancer Center, Washington D.C.
Studije za Немалоклетни карцином плућа u drugim gradovima
- Houston, TX143 студија
- New York City, NY123 студија
- Arlington, VA111 студија
- Nashville, TN97 студија
- Los Angeles, CA92 студија
- Boston, MA87 студија
- St. Louis, MO68 студија
- Baltimore, MD60 студија
- San Antonio, TX60 студија
- Chicago, IL59 студија
- Columbus, OH57 студија
- Seattle, WA55 студија
Ostale studije u gradu Washington
- Рак (све врсте)60 студија
- Рак дојке44 студија
- Метастатски карцином44 студија
- Рак плућа41 студија
- Рак простате39 студија
- Гојазност34 студија
- Колоректални карцином28 студија
- Кардиоваскуларне болести27 студија
- Рак бешике26 студија
- Рак јајника25 студија
- Лимфом23 студија
- Hronična limfocitna leukemija22 студија
Sa sajta ClinicalTrials.gov, podaci preuzeti 15. 11. 2026.. Svaka studija ima svoje kriterijume za uključivanje; tim studije odlučuje ko može da učestvuje.